Patrick Campbell

After showing a significant impact on reduction of cardiovascular events, a slew of subgroup analyses were performed examining use of icosapent ethyl using data derived from REDUCE-IT.

Trial investigator Deepak Bhatt, MD, MPH, discusses how use of rivaroxaban in a clinical setting has changed as a result of the COMPASS trial.

Lead investigator of REDUCE-IT trials discusses the impact of trial results and what that means for EPA-based treatments going forward.

Use of rivaroxaban (Xarelto) plus aspirin was found to reduce cardiovascular and major limb events in a secondary analysis of the COMPASS trial.

OSA patients with certain traits experienced a 73% reduction in AHI events from oral appliance treatment.

A recent study examining the effectiveness of an offline, automated smartphone-based AI system could be giving physicians a glimpse into the future of eye screening.

Drinking more than 3 servings of caffeinated beverages per day was associated with an increase in migraine headaches.

Individuals with increased levels of inflammation after 1 year were associated higher rates of all-cause mortality and mortality attributable to cardiovascular disease and cancer.

Strict adherence to a plant-based diet could result in a 16% reduction in risk of having a cardiovascular disease.

A 24-week randomized clinical trial found PRT-P led to improvements in social communication skills among children with ASD.

AbbVie's submitted NDA for elagolix for the treatment of heavy menstrual bleeding associated with uterine fibroids in women is supported by the results of 2 phase 3 studies.

Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant associated with low rates of major bleeding and arterial thromboembolism in the PAUSE study.

Obesity, smoking, and other trends are slowing the rate of decline, and even causing increases, of cardiovascular disease in many high-income countries across the world.

Deepak Bhatt, MD, discusses the results of the COMPASS trial and how they have impacted clinical practice.

Steven Edelman, MD, clinical professor of medicine at UC San Diego, discusses glucose control among pediatric patients after a trial into the efficacy of inhaled insulin opened enrollment earlier this week.

A study presented at ASRS 2019 found that the ranibizumab biosimilar (razumab) was noninferior to ranibizumab after 1 month of treatment.

A former D.C. healthcare attorney and founder of the Macular Degeneration Association discusses legal problems faced by retina specialists when providing care to their patients with AMD.

Chirag Jhaveri, MD, took part in a Q&A about the results of the phase 3 HAWK and HARRIER studies examining brolucizumab for treatment of nAMD.

Results of a study from investigators at the Retina Center of Minnesota found that same-day injections were preferred by more than 97% of patients.

Manjot Gill, MD, discusses the results of her study which found early diagnosis and treatment of neovascular age-related macular degeneration could help save a patient’s vision.

Artificial intelligence could be the future of detecting certain diseases in the eye, after a study presented at ASRS 2019 found that the EyeArt system was effective in detecting referable diabetic retinopathy from images.

Investigators presented 36-month results of a study which found that treatment with a single intravitreal injection of the FAi provided anti-inflammatory treatment for 3 years in patients with non-infectious uveitis affecting the posterior segment of the eye

Additional analyses of the phase 2 BOULEVARD trial, which found faricimab not only led to improved best-corrected visual acuity and central subfield thickness from baseline, but also provided anatomical benefits and displayed a potential for extended durability compared to anti-VEGF monotherapy, were presented during ASRS 2019

Medical Director of the Macular Degeneration Association discusses how the evolution of anti-VEGF treatments has changed the landscape of AMD care and the lives of patients.

Results of a study presented at ASRS 2019 found that biweekly anti-VEGF dosing may be an effective treatment for treating nAMD refractory to standard monthly dosing.

While often seen in a negative light, some physicians have found ways to incorporate electronic medical records to improve their practice.

Eleonora Lad, MD, PhD, presented results of a post-hoc analysis evaluating the impact of baseline characteristics on lesion progression in patients receiving APL-2 for geographic atrophy at ASRS 2019.

Carl Regillo, MD, of Wills Eye, and Michael Stewart, of the Mayo Clinic, discuss changes they would like to see in their speciality at ASRS 2019.

W. Lloyd Clark, MD, of Palmetto Retina Center, discusses clinical implications of the 52-week PANORAMA results, which found treatment with intravitreal aflibercept injections could reverse disease progression in patients with moderately severe to severe NPDR.

Jeffrey Heier, MD, presented 24-month results of the PRO-CON study, which found no statistical difference in conversion rates in fellow eyes regardless of prophylactic treatment with aflibercept injections, at ASRS 2019.